Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02701062 · ClinicalTrials.gov registry record · Phase 4

AtriClip® Left Atrial Appendage Exclusion Concomitant to Structural Heart Procedures (ATLAS)

A Phase 4 study of Post Operative Atrial Fibrillation, sponsored by AtriCure.

Completed
Registry status
Phase 4
Development phase
562
Enrollment target
20
Study locations

NCT02701062 is a Phase 4 study of Post Operative Atrial Fibrillation that has completed, run by AtriCure. The registered enrollment target is 562 participants. The trial reports 20 study locations across 14 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02701062, a Phase 4 study of Post Operative Atrial Fibrillation, has completed, sponsored by AtriCure.

COMPLETED
Registry status
Phase 4
Development phase
562 participants
Enrollment target
20
Study locations

Study Summary

Patients without a documented history of Atrial Fibrillation (AF) and will undergo a valve or Coronary Artery Bypass Graft (CABG) procedure with direct visual access to the Left Atrial Appendage (LAA) will be eligible to participate. Patients enrolled will be randomized 2:1 (2 with AtriClip to 1 without AtriClip. Subjects who develop Post-operative Atrial Fibrillation (POAF) and receive the AtriClip will be followed for 365 days post index procedure.

Interventions

  • DEVICE AtriClip® Gillinov-Cosgrove™ LAA Exclusion Systems
  • DRUG Anticoagulation Therapy

Study Locations (20)

New York

  • NYU Langone Medical Center - New York
  • Mount Sinai -St. Luke's - New York
  • Icahn School of Medicine at Mount Sinai - New York

California

  • Sharp Memorial Hospital - San Diego
  • Stanford University - Stanford

Indiana

  • St Francis Heart Hospital - Indianapolis
  • St. Vincent Heart Center, Inc. - Indianapolis

Ohio

  • The Christ Hospital -Linder Research Center - Cincinnati
  • Tri-Health - Cincinnati

Tennessee

  • Wellmont CVA Heart Institute - Kingsport
  • Cardiovascular Surgery Clinic - Memphis

Florida

  • Orlando Health Heart Institute - Orlando

Georgia

  • Emory St Joseph Hospital - Atlanta

Kansas

  • University of Kansas Hospital - Kansas City

Trial Details

FieldValue
Enrollment Target 562 participants
Start Date 2016-02
Est. Completion 2019-06-01
Phase Phase 4

Sponsor

AtriCure

23 total trials

What the Registry Record Tells You About NCT02701062

The ClinicalTrials.gov registry entry for NCT02701062 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 562 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AtriCure, which has 23 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Post Operative Atrial Fibrillation appearing as the primary indexed condition, and to 2 interventions - of which AtriClip® Gillinov-Cosgrove™ LAA Exclusion Systems is the first listed.

NCT02701062 reports 20 study locations spanning 14 distinct geographic areas - top geographies include New York, California, Indiana.

Frequently Asked Questions

What is clinical trial NCT02701062 about?

NCT02701062 is a clinical study titled "AtriClip® Left Atrial Appendage Exclusion Concomitant to Structural Heart Procedures (ATLAS)". Patients without a documented history of Atrial Fibrillation (AF) and will undergo a valve or Coronary Artery Bypass Graft (CABG) procedure with direct visual access to the Left Atrial Appendage (LAA) will be eligible to participate. Patients enrolled will be randomized 2:1 (2 with AtriClip to 1 wit...

What is the current status of trial NCT02701062?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 562 participants. The study started on 2016-02. Estimated completion is 2019-06-01.

What conditions does trial NCT02701062 study?

This clinical trial studies the following conditions: Post Operative Atrial Fibrillation.

What interventions are being tested in trial NCT02701062?

The interventions under investigation include: AtriClip® Gillinov-Cosgrove™ LAA Exclusion Systems (DEVICE), Anticoagulation Therapy (DRUG).

Who is sponsoring clinical trial NCT02701062?

This trial is sponsored by AtriCure, which has 23 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02701062 being conducted?

This trial has 20 study locations across California, Florida, Georgia, Indiana, Kansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Post Operative Atrial Fibrillation

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.